Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: Absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup

Haematologica

Volumn 90, Issue 2, 2005, Pages 200-206

  Petit, Barbara ^a   Chaury, Marie Pierre ^b   Le Clorennec, Christophe ^d   Jaccard, Arnaud ^b,d   Gachard, Nathalie ^c   Moalic Judge, Sandra ^e   Labrousse, François ^a   Cogné, Michel ^d   Bordessoule, Dominique ^b,d   Feuillard, Jean ^c,d  

^a Laboratoire d'Anatomie Pathologique   (France)

^b Service d'Hematologie Clinique   (France)

^c Laboratoire d'Hematologie   (France)

^d CNRS   (France)

^e UNIVERSITY OF LIMOGES   (France)

Author keywords

IRF4; Ki67; Lymphoma; Memory B cells

Indexed keywords

C REACTIVE PROTEIN; CD23 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; PROTEIN BCL 6; SYNDECAN 1; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CANCER SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MAJOR CLINICAL STUDY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; KI-67 ANTIGEN; LYMPHOMA; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044392114     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, LARC press. 2001
2. Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma-an update on recent advances. Histopathology 2002; 40:117-26.
3. Berger F, Isaacson PG, Piris MA, Harris NL, Muller-Hermelink HK, Nathwani BN, et al. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. In: Jaffe E, Harris NL, Stein H, Vardiman JW, eds. Tumours of haematological and lymphoid tissues. Lyon, International Agency for Research in Cancer (IARC), 2001.
4. Lennert K, Feller AC. Histopathology of Non-Hodgkin's lymphomas (Based on the updated Kiel Classification). Berlin, Springer-Verlag. 1990.
5. Conconi A, Bertoni F, Pedrinis E, Motta T, Roggero E, Luminari S, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001;98: 781-6.
6. Algara P, Mateo MS, Sanchez-Beato M, Mollejo M, Navas IC, Romero L, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lympoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299-304.
7. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of Vk gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994;83: 3647-53.
8. Ciric B, VanKeulen V, Rodriguez M, Kyle RA, Gertz MA, Pease LR. Clonal evolution in Waldenstrom macroglobulinemia highlights the functional role of B-cell receptor. Blood 2001;97:321-3.
9. Sahota SS, Forconi F, Ottensmeier CH, Provan D, Oscier DG, Hamblin TJ, et al. Typical Waldenstrom's macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002;100:1505-7.
10. Chacon JI, Mollejo M, Munoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100: 1648-54.
11. Nathwani BN, Anderson JR, Armitage JO, Cavaili F, Diebold J, Drachenberg MR, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999;17:2486-92.
12. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950-6.
13. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000;96:852-8.
14. Andriko JA, Swerdlow SH, Aguilera NI, Abbondanzo SL. Is lymphoplasmacytic lymphoma/immunocytoma a distinct entity? A clinicopathologic study of 20 cases. Am J Surg Pathol 2001;25:742-51.
15. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-6.
16. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-60
17. Cox D. Regression models and life tables. J Stat Soc 1972;34:187-92.
18. Swerdlow SH, Zukerberg LR, Yang WI, Harris NL, Williams ME. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements. Am J Surg Pathol 1996;20:627-40.
19. Van Huyen JP, Molina T, Delmer A, Audouin J, Le Tourneau A, Zittoun R, et al. Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol 2000; 24: 1581-92.
20. Liu YJ, Banchereau J. Regulation of B-cell commitment to plasma cells or to memory B cells. Semin Immunol 1997; 9:235-40.
21. Loenen WA, De Vries E, Gravestein LA, Hintzen RQ, Van Lier RA, Borst J. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol 1992; 22: 447-55.
22. Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, et al. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica 1998;83:398-402.
23. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556-65.
24. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-6.
25. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, et al Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114-23.
26. Franco V, Florena AM, Ascani S, Paulli M, Salvato M, Pileri SA. CD27 distinguishes two phases in bone marrow infiltration or splenic marginal zone lymphoma. Histopathology 2004;44: 381-6.
27. MacLennan IC, Garcia de Vinuesa C, Casamayor-Palleja M. B-cell memory and the persistence of antibody responses. Phil Trans R Soc Lond B Biol Sci 2000;355:345-50.
28. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
29. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:575-82.
30. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998;31:351-7.
31. Damle RN, Wasil T, Fais F, Ghiotto F, Valette A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
32. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997;17:226-30.
33. Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 2003;21: 205-30.
34. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997;275:540-3.
35. Falini B, Fizzotti M, Pucciarini A, Bigema B, Marafioti T, Gambacorta M, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-92.
36. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol 2000;165:5462-71.
37. Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, Yoshida M, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol 1996;16:1283-94.
38. Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, Atchison ML. PU.1 recruits a second nuclear factor to a site important for immunoglobulin k 3′ enhancer activity. Mol Cell Biol 1992;12:368-78.
39. Pongubala JM, Van Beveren C, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, et al. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science 1993;259:1622-5.
40. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995; 9:1377-87.
41. Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000;14:449-56.
42. Camacho FI, Algara P, Mollejo M, Garcia JF, Montalban C, Martinez N, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003;27:762-71.
43. Chang CC, Lorek J, Sabath DE, Li Y, Chitambar CR, Logan B, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002;100:4671-5.
44. Ito M, Iida S, Inagaki H, Tsuboi K, Komatsu H, Yamaguchi M, et al. MUM1/IRF4 expression is an unfavorable prognostic ractor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res 2002;93:685-94.
45. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503.
46. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-82.
47. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 2003;88:80-93.